将二甲双胍重新用于治疗特发性或长新冠耳鸣：采用病理生理学和药理学方法进行自我报告。
Repurposing metformin to manage idiopathic or long COVID Tinnitus: self-report adopting a pathophysiological and pharmacological approach.
机构信息
Pharmacology Department, College of Medicine, Minia University, Minya, 61111, Egypt.
出版信息
Inflammopharmacology. 2024 Apr;32(2):945-948. doi: 10.1007/s10787-023-01421-8. Epub 2024 Jan 31.
Abstract
Chronic tinnitus is a common neurological disorder that affects millions of patients globally with no available successful pharmacotherapy. It can be extremely bothersome to some patients to the extent that it occasionally qualifies as a disability that can hinder them from leading a normal life. In this short communication, the author discusses how he suffered from idiopathic tinnitus and how he managed to adopt a combined pathophysiological and pharmacological approach to the reason for the first time in the medical literature that low-dose metformin might be safely and effectively repurposed to manage at least a subset of tinnitus patients while discussing the potential role of adenosine receptor agonists as potential future tinnitus therapeutics.
摘要
慢性耳鸣是一种常见的神经障碍，影响着全球数以百万计的患者，目前尚无有效的药物治疗方法。对于一些患者来说，耳鸣极其令人困扰，严重程度足以认定为残疾，使其无法过上正常的生活。在这篇简短的交流文章中，作者讨论了自己患有特发性耳鸣的经历，以及他如何首次在医学文献中采用综合病理生理学和药理学方法来治疗耳鸣。他还讨论了低剂量二甲双胍可能被安全有效地重新用于治疗至少一部分耳鸣患者的可能性，同时探讨了腺苷受体激动剂作为潜在未来耳鸣治疗药物的潜在作用。
相似文献
1
Repurposing metformin to manage idiopathic or long COVID Tinnitus: self-report adopting a pathophysiological and pharmacological approach.将二甲双胍重新用于治疗特发性或长新冠耳鸣：采用病理生理学和药理学方法进行自我报告。
Inflammopharmacology. 2024 Apr;32(2):945-948. doi: 10.1007/s10787-023-01421-8. Epub 2024 Jan 31.
2
Effect of Nitrous Oxide as a Treatment for Subjective, Idiopathic, Nonpulsatile Bothersome Tinnitus: A Randomized Clinical Trial.一氧化二氮（笑气）治疗主观性、特发性、非搏动性烦扰性耳鸣的效果：一项随机临床试验。
JAMA Otolaryngol Head Neck Surg. 2018 Sep 1;144(9):781-787. doi: 10.1001/jamaoto.2018.1278.
3
New onset tinnitus in the absence of hearing changes following COVID-19 infection.新冠病毒感染后出现听力变化之前的新发耳鸣。
Am J Otolaryngol. 2022 Jan-Feb;43(1):103208. doi: 10.1016/j.amjoto.2021.103208. Epub 2021 Sep 10.
4
[Pharmacotherapy of acute and chronic tinnitus].[急性和慢性耳鸣的药物治疗]
Med Monatsschr Pharm. 2012 Nov;35(11):396-406; quiz 407-8.
5
Pharmacotherapy of Tinnitus.耳鸣的药物治疗。
Curr Top Behav Neurosci. 2021;51:193-212. doi: 10.1007/7854_2020_169.
6
Is COVID-19 associated with self-reported audio-vestibular symptoms?新冠病毒（COVID-19）是否与自我报告的听觉-前庭症状相关？
Int J Audiol. 2022 Oct;61(10):832-840. doi: 10.1080/14992027.2021.1957161. Epub 2021 Aug 9.
7
Tinnitus Self-Efficacy and Other Tinnitus Self-Report Variables in Patients With and Without Post-Traumatic Stress Disorder.患有和未患有创伤后应激障碍的患者的耳鸣自我效能及其他耳鸣自我报告变量
Ear Hear. 2016 Sep-Oct;37(5):541-6. doi: 10.1097/AUD.0000000000000290.
8
Tinnitus emerging in the context of a COVID-19 infection seems not to differ in its characteristics from tinnitus unrelated to COVID-19.在新冠病毒感染背景下出现的耳鸣，其特征似乎与与新冠病毒无关的耳鸣并无不同。
Front Neurol. 2022 Sep 9;13:974179. doi: 10.3389/fneur.2022.974179. eCollection 2022.
9
Pharmacotherapy for severe, disabling, subjective, idiopathic tinnitus: 2005-2006.2005 - 2006年重度、致残性、主观性特发性耳鸣的药物治疗
Int Tinnitus J. 2006;12(2):161-71.
10
COVID-19 and tinnitus: an initiative to improve tinnitus care.新型冠状病毒肺炎与耳鸣：改善耳鸣护理的一项举措。
Int J Audiol. 2023 Sep;62(9):826-834. doi: 10.1080/14992027.2022.2104175. Epub 2022 Aug 2.
引用本文的文献
1
Emerging small-molecule antiviral agents in long COVID prevention.用于预防新冠后遗症的新型小分子抗病毒药物
Front Pharmacol. 2024 Oct 9;15:1457672. doi: 10.3389/fphar.2024.1457672. eCollection 2024.
本文引用的文献
1
The African Kelleni's roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one.非洲使用硝唑尼特和广谱抗菌药物来避免重新回到 COVID-19 原点的路线图。
Inflammopharmacology. 2023 Dec;31(6):3335-3338. doi: 10.1007/s10787-023-01263-4. Epub 2023 Jun 16.
2
Real-world practice of the Egyptian Kelleni's protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH.1.1 subvariants: a multi-purpose protocol.在 SARS-CoV-2 奥密克戎 BA.5.2.1.7、XBB 1.5 和 CH.1.1 亚变种不断变化的嗜性中实施埃及 Kelleni 方案的真实世界实践：一种多用途方案。
Inflammopharmacology. 2023 Jun;31(3):1559-1560. doi: 10.1007/s10787-023-01180-6. Epub 2023 Mar 16.
3
Nutritional deficiencies that may predispose to long COVID.可能导致长新冠的营养缺乏。
Inflammopharmacology. 2023 Apr;31(2):573-583. doi: 10.1007/s10787-023-01183-3. Epub 2023 Mar 15.
4
Correction: Chen et al. The Chemerin/CMKLR1 Axis Is Involved in the Recruitment of Microglia to Aβ Deposition through p38 MAPK Pathway. 2022, , 9041.更正：陈等人。趋化素/CMKLR1轴通过p38丝裂原活化蛋白激酶途径参与小胶质细胞向Aβ沉积部位的募集。2022年，，9041。
Int J Mol Sci. 2022 Dec 28;24(1):506. doi: 10.3390/ijms24010506.
5
A genome-wide association study of tinnitus reveals shared genetic links to neuropsychiatric disorders.一项针对耳鸣的全基因组关联研究揭示了与神经精神疾病的共同遗传关联。
Sci Rep. 2022 Dec 29;12(1):22511. doi: 10.1038/s41598-022-26413-6.
6
Real-life practice of the Egyptian Kelleni's protocol in the current tripledemic: COVID-19, RSV and influenza.埃及凯莱尼方案在当前新冠、呼吸道合胞病毒和流感三重疫情中的实际应用。
J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.12.007. Epub 2022 Dec 10.
7
Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild-moderate COVID-19 and prevention of post-COVID cognitive impairment.甘草酸和乳香酸，金营养保健品：针对轻度至中度 COVID-19 的多靶点治疗和预防 COVID 后认知障碍。
Inflammopharmacology. 2022 Dec;30(6):1977-1992. doi: 10.1007/s10787-022-01062-3. Epub 2022 Sep 22.
8
Otolaryngology adverse events following COVID-19 vaccines.耳鼻喉科与 COVID-19 疫苗相关的不良事件。
Eur Rev Med Pharmacol Sci. 2022 Jun;26(11):4113-4116. doi: 10.26355/eurrev_202206_28981.
9
Self-reported Tinnitus and Vertigo or Dizziness in a Cohort of Adult Long COVID Patients.一组成人长期新冠患者的自我报告耳鸣及眩晕或头晕情况
Front Neurol. 2022 Apr 25;13:884002. doi: 10.3389/fneur.2022.884002. eCollection 2022.
10
Effects of Patient-Generated Health Data: Comparison of Two Versions of Long-Term Mobile Personal Health Record Usage Logs.患者生成的健康数据的影响：两种版本的长期移动个人健康记录使用日志的比较。
Healthcare (Basel). 2021 Dec 28;10(1):53. doi: 10.3390/healthcare10010053.
Zotero 插件